ARS Pharmaceuticals, Inc. — FY 2023 Form 10-K
Reporting period: Fiscal year ended December 31, 2023. The filing was signed March 21, 2024. ARS is a pre-commercial biopharmaceutical company whose business is substantially dependent on developing neffy, an investigational needle-free intranasal epinephrine product.
Business context and financial results
neffy had no commercial sales and was not FDA-approved at year-end. ARS reported no product revenue; collaboration revenue was $30,000, compared with $1.316 million in 2022.
| Metric | 2023 | 2022 |
|---|---|---|
| Research and development expense | $20.3 million | $18.4 million |
| General and administrative expense | $47.3 million | $18.5 million |
| Total operating expenses | $67.6 million | $36.8 million |
| Operating loss | $67.5 million | $35.5 million |
| Other income, net | $13.2 million | $1.0 million |
| Net loss | $54.4 million | $34.7 million |
| Net loss per share, basic and diluted | $0.57 | $0.87 |
| Net cash used in operating activities | $59.3 million | $40.1 million |
Operating expenses rose 83%, chiefly reflecting a $13.6 million increase in neffy pre-commercial launch spending and higher payroll and consulting costs. Net loss increased 57%; substantially higher interest income partly offset the increase in operating loss. Stock-based compensation was $9.2 million, versus $5.8 million.
At December 31, 2023, cash and cash equivalents were $71.0 million and short-term investments were $157.4 million, totaling $228.4 million. Total assets were $233.2 million, total liabilities $2.4 million, and stockholders’ equity $230.8 million. The company had no bank debt outstanding; it repaid its Silicon Valley Bank loan in November 2022. No product gross margin is available because ARS had no product sales.
Material developments and unusual items
- On September 19, 2023, the FDA issued a Complete Response Letter (CRL) for the neffy NDA, requesting a repeat-dose PK/PD study under allergen-induced allergic rhinitis and updated testing for nitrosamine impurities.
- ARS reported February 2024 topline repeat-dose study results as comparable to or better than repeat-dose intramuscular injection, and said updated nitrosamine testing detected no measurable levels. These are post-year-end company-reported results; FDA approval remained uncertain.
- The FDA advisory committee had voted 16–6 in favor of a favorable benefit-risk assessment for adults and 17–5 for children weighing at least 30 kg. The committee’s recommendations are non-binding.
- ARS planned to resubmit its NDA early in Q2 2024 and anticipated an FDA action in the middle of the second half of 2024. Its EU application was under review, with a decision expected by mid-2024. These are management expectations, not assured outcomes.
- ARS initiated a 20% workforce reduction in September 2023 following the CRL, incurring $0.6 million of termination costs. Management cited cash conservation pending the anticipated FDA action.
- In February 2023, ARS terminated its Recordati licensing arrangement and reacquired the related rights. It paid €3.0 million and may owe additional regulatory and commercial milestones and sales-based payments.
- The company corrected an immaterial error related to a retrospective insurance policy recorded in the 2022 merger: it removed a $3.6 million asset and reduced additional paid-in capital. The filing says the correction was immaterial.
Outlook, liquidity, and principal risks
Management said existing cash and investments were expected to fund planned operations for at least three years, including the NDA resubmission and review, additional neffy studies, pre-commercial preparation, and a potential launch. The estimate is subject to uncertainty; spending is expected to increase with commercialization, and the company may need additional capital if plans, timing, or costs change. ARS expects G&A spending to rise in 2024 to support commercial preparation; it expected R&D spending to decrease based on planned development activity.
Key risks include dependence on a single product candidate; FDA or EMA delay, rejection, or further study requirements; market adoption, pricing, coverage and reimbursement uncertainty; competition from injectable products and other developing epinephrine candidates; reliance on third-party manufacturers and suppliers; and patent challenges. ARS disclosed an appeal concerning U.S. Patent No. 10,682,414 and an opposition to a European patent. Outcomes were uncertain, and the company said any potential loss could not be reasonably estimated; no liability was recorded.
The 2023 financial statements received an unqualified audit opinion. Management concluded disclosure controls and internal control over financial reporting were effective as of December 31, 2023; the auditor was not engaged to audit internal control effectiveness. The company reported no cash dividends and no issuer share repurchases.
Important facts for investors to verify
- Whether the FDA accepts the CRL response, confirms the stated review timetable, and approves neffy with commercially viable labeling.
- Final, complete study data and the FDA’s assessment of repeat dosing and nitrosamine testing, rather than company-reported topline results.
- Actual cash burn and runway against the stated three-year estimate, including pre-launch costs and any additional financing needs.
- EU review outcome, partner progress in Japan and China, and any resulting milestone, supply, or royalty economics.
- Status and potential impact of the U.S. patent appeal and European patent opposition, as well as the terms of Recordati-related contingent payments.
- Whether payor coverage, reimbursement, pricing, manufacturing readiness, and patient and physician uptake support management’s commercialization assumptions.